Alvotech (ALVO) Q1 2026 Earnings Call Transcript
Alvotech (ALVO) Q1 2026 Earnings Call Transcript
Seeking Alpha5/8/2026Neutral
ALVOW
Alvotech WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
0.22
52W High
$2.46
52W Low
$0.13
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
-36.30%
Forward P/E
—
PEG Ratio
—
About Alvotech Warrant
Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland.
Fundamentals
| Revenue (TTM) | $494.61M |
| Gross Profit (TTM) | $300.04M |
| EBITDA | $75.73M |
| Operating Margin | -11.10% |
| Return on Equity | 0.00% |
| Return on Assets | 2.19% |
| Revenue/Share (TTM) | $1.68 |
| Book Value | $-0.54 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | -99.00% |
| Quarterly Revenue Growth (YoY) | -38.90% |
| Shares Outstanding | 0 |
| Float | $140.79M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—
Latest News
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALVOW and any ticker you trade — then tracks every position and per-strategy win rate.
Data last updated: 9/7/2026